Prognostic value of lung immune prognostic index in stage I non-small cell lung cancer treated with stereotactic body radiotherapy: A two-center study

Table 1 Patients and disease characteristics: Stratification by lung immune prognostic index scores

Characteristics	Poor LIPI (n = 35)	Good LIPI (n = 33)	P value
Gender			0.569
Male	20	17
Female	15	16
Age (years)	67.7 ± 9.2	67.5 ± 10.1	0.934
≤ 65	8	11
> 65	27	22
Karnofsky score			0.973
90-100	7	10
70-80	28	23
Radiation dose			0.175
48 Gy/4 Fr	11	14
50 Gy/5 Fr	24	19
Clinical stage			0.221
Ia	13	18
Ib	22	15

LIPI: Lung immune prognostic index.

Table 2 Cox proportional hazards regression for overall survival

Variable	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Gender (male vs female)	2.334 (0.859-6.244)	0.097
Age (≤ 65 vs > 65)	0.550 (0.263-1.149)	0.112
Karnofsky score (90/100 vs 70/80)	1.236 (0.395-3.862)	0.716
Radiation dose (48 Gy vs < 50 Gy)	0.508 (0.227-1.136)	0.099
Clinical stage (Ia vs Ib)	2.040 (0.732-5.681)	0.173
LIPI scores (good vs poor)	0.547 (0.312-0.839)	0.004	0.242 (0.104-0.566)	0.001

CI: Confidence interval; LIPI: Lung immune prognostic index; HR: Hazard ratio; OS: Overall survival.